Synthesis and Properties of Secondary Thiocarbamoylsilanes
作者:Toshiaki Murai、Rumi Hori
DOI:10.1246/bcsj.20090231
日期:2010.1.15
influenced by the substituents on the aromatic ring: electron-withdrawing groups decreased the yield. No reaction occurred with thioformamides having secondaryalkyl groups on the nitrogen atom, whereas the reaction of those with primary alkyl groups proceeded smoothly to form the corresponding thiocarbamoylsilanes. Initially, deprotonation takes place at the nitrogen atom to generate lithium thioimidates
二级硫代甲酰胺与过量的 LDA 和 Me 3 SiCl 在 -78 °C 下反应。甲硅烷基被选择性地引入到硫代羰基碳原子上,得到仲硫代氨基甲酰基硅烷。Me 2 PhSiCl 和 t-BuMe 2 SiCl 的使用产生了产率降低的类似产品。虽然多种N-芳基甲基硫代甲酰胺参与了硅烷化反应,但产物的产率受芳环上取代基的影响:吸电子基团降低了产率。与氮原子上具有仲烷基的硫代甲酰胺不发生反应,而具有伯烷基的硫代甲酰胺反应顺利进行,形成相应的硫代氨基甲酰基硅烷。最初,在氮原子上发生去质子化以生成硫代亚胺酸锂,然后用氯硅烷甲硅烷基化,形成硫代亚胺甲硅烷酯。过量的 LDA 使亚胺酸碳原子上的硫代亚胺甲硅烷基去质子化,生成硫代亚胺甲硅烷基锂,其经历反向布鲁克重排以形成在亚胺碳原子上带有甲硅烷基的硫代亚胺酸锂。中间体的水解可能导致二级硫代氨基甲酰基硅烷的形成。在硫代氨基甲酰基硅烷的紫外-可见光谱中,归因于 n-π*
[EN] BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM<br/>[FR] BICYCLO-PYRAZOLES ACTIFS INHIBITEURS DE KINASE, PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CEUX-CI
申请人:PHARMACIA ITALIA SPA
公开号:WO2004013144A1
公开(公告)日:2004-02-12
The present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a pyrrolo-pyrazole or pyrazolo-azepine. The invention also provides specific pyrrolo-pyrazoles and pyrazolo-azepines, useful intermediates, a library comprising at least two of them, a process for their preparation and the pharmaceutical compositions containing them, which are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.
[EN] BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM<br/>[FR] BICYCLO-PYRAZOLES ACTIFS UTILES COMME INHIBITEURS DE KINASE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
申请人:PHARMACIA ITALIA SPA
公开号:WO2004014374A1
公开(公告)日:2004-02-19
The present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a pyrazole-tetrahydro pyridine derivative. The invention also provides specific pyrazole-tetrahydro pyridines, a library comprising at least two of them, a process for their preparation and the pharmaceutical compositions containing them, which are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.
Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
申请人:Villa Manuela
公开号:US20060135508A1
公开(公告)日:2006-06-22
The present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a pyrrolo-pyrazole or pyrazolo-azepine. The invention also provides specific pyrrolo-pyrazoles and pyrazolo-azepines, useful intermediates, a library comprising at least two of them, a process for their preparation and the pharmaceutical compositions containing them, which are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.
Anti-cancer compositions and methods are described including one or more isothiocyanates and/or isoselenocyanates. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation.